🔗 Share this article

Given that the US proceeds with sweeping revisions to its vaccination guidelines, a particular individual appears unexpectedly: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who first made her name by questioning coronavirus shots in the global health crisis and has concentrated on possible fatalities after COVID-19 immunization in her short time at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Immunization Schedule

Public health authorities were set to announce radical revisions to the pediatric vaccination calendar recently, synchronizing the US with the Danish national calendar, according to reports – a substantial departure that would place the US at odds with many the global community with insufficient data for public health gain. This reveal has been pushed back until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is listed to present at the meeting. She was recently named acting director of the FDA’s CDER, the fifth person to lead the division this calendar year.

Consolidating Power at the Agency

The acting appointment may indicate a closer partnership between the pharmaceutical and vaccine centers as Høeg and Prasad solidify control at the regulatory agency – and it points to a greater focus upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for halting certain childhood shot schedules in the US in order to be more like the Danish model, a society with universal health coverage and a population about the population of Wisconsin’s.

So far statements, she has kept her attention on vaccines – traditionally the responsibility of Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Doubts Over Qualifications

Høeg has no obvious background in drug development, oversight or leadership, which has been customary for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in leading a major agency. She is not an expert in pharmaceutical oversight.”

Former directors of CBER would “understand regulatory frameworks and the underlying principles of medication creation”, noted Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that previous people who ran the center have had.”

This division has an vast range of responsibilities at the agency, Woodcock pointed out.

“Everybody just focuses on the new drug program, but the generic program approves a multitude of generic drugs. There is also a biosimilars program, over-the-counter program and more, and every single one have to be looked after,” she noted. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a significant leadership element to the role, which manages in excess of 5,000 employees. “It is a huge administrative position, if you perform it correctly,” she added.

Official Statement and Controversial Policies

In response to questions about Høeg’s fitness for the role and whether this selection indicates more teamwork among agency officials on immunizations, a spokesperson said that the “inquiries are based on incorrect presumptions”.

“Her experience matches the responsibilities of her job,” the official stated, noting the time Dr. Høeg spent guiding the FDA commissioner on “drug safety and approval science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a disputed one-day drug-approval program that apparently troubled her former heads. “How are these medications being chosen for this voucher program? Who takes the choices?” Dr. Howard questioned. “There is a lot of secrecy happening at the agency right now.”

Broadly speaking, he said, “the FDA seems to be moving towards more relaxed rules of all drugs, except for shots.”

Public History on Immunizations

Regarding immunizations, Høeg has a clearer, if problematic, history, critics have noted. She released a analysis using unverified public submissions to assess the frequency of myocarditis following Covid vaccination. She consulted for the Florida chief medical officer Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccinations are more dangerous than they are.

Included in her “desired changes” for the incoming administration featured revising guidelines for recently developed shots and discontinuing “non-essential” immunizations, she stated following the vote on a audio program. At the agency, Dr. Høeg has according to sources proposed excluding young men from getting Covid vaccinations.

“She’s an complete dogmatist who starts off with her preconceived notions and reverse-engineers to accommodate the evidence in a highly disingenuous, fraudulent fashion,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of other contrarians, {like|